| 40.59 -0.14 (-0.34%) | 10-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 48.72 | 1-year : | 56.91 |
| Resists | First : | 41.72 | Second : | 48.72 |
| Pivot price | 39.76  |
|||
| Supports | First : | 39.21 | Second : | 37.65 |
| MAs | MA(5) : | 40.44 |
MA(20) : | 39.7 |
| MA(100) : | 39.67 |
MA(250) : | 40.5 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 69.2 |
D(3) : | 68 |
| RSI | RSI(14): 54.5 |
|||
| 52-week | High : | 50.99 | Low : | 27.98 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ XENE ] has closed below upper band by 26.3%. Bollinger Bands are 23.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 41.43 - 41.59 | 41.59 - 41.73 |
| Low: | 39.36 - 39.56 | 39.56 - 39.73 |
| Close: | 40.38 - 40.71 | 40.71 - 40.99 |
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Sat, 05 Oct 2024
Dimensional Fund Advisors LP Raises Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Thu, 03 Oct 2024
Analysts Offer Predictions for Xenon Pharmaceuticals Inc.'s Q3 2024 Earnings (NASDAQ:XENE) - MarketBeat
Thu, 03 Oct 2024
Thrivent Financial for Lutherans Invests $1.68 Million in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Wed, 02 Oct 2024
Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference - The Manila Times
Wed, 02 Oct 2024
Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference - StockTitan
Sat, 14 Sep 2024
Insiders At Xenon Pharmaceuticals Sold US$1.6m In Stock, Alluding To Potential Weakness - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 76 (M) |
| Shares Float | 70 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 100.9 (%) |
| Shares Short | 3,600 (K) |
| Shares Short P.Month | 3,340 (K) |
| EPS | -2.74 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.14 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -19 % |
| Return on Equity (ttm) | -26.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.09 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -154 (M) |
| Levered Free Cash Flow | -104 (M) |
| PE Ratio | -14.87 |
| PEG Ratio | -1.5 |
| Price to Book value | 3.64 |
| Price to Sales | 0 |
| Price to Cash Flow | -20.03 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|